Published: 27. June, 2023

On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company…

On 27 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive US license and collaboration agreement with Ventis Pharma Corporation – a biopharmaceutical company focused on developing and formulating innovative pain management therapies – for the development and commercialization of CT001 for the US market. Under the agreement both parties, Cessatech and Ventis Pharma will share costs and net profits 50/50 with the potential to generate revenues from 2024, much earlier than originally anticipated.

  • Cessatech and Ventis Pharma enter a co-development and commercialization royalty license agreement for CT001 sharing net profits
  • CT001 will be part of US Ventis Pharma’s distribution of innovative pain management therapies under an early access program in the US
  • A large US market of more than 15 million pediatric injuries or procedural pain incidents, categorized as moderate to severe, giving the partnership a large market opportunity, with potential for revenues in 2024

Jes Trygved, CEO Cessatech
“The US is the largest market and we believe the partnership with Ventis represents the best opportunity to get CT001 to a much-needed pain management of children. With this partnership CT001 can potentially be available to patients in the US already by the next year – which is 3-4 years earlier than originally anticipated – as we leverage the skills and operations of our partner. This collaboration is a good illustration of our strategy to build our business by working with partners who can help us successfully navigate the regulatory and commercial landscape in different territories. Ventis will potentially also be involved in the further development of our pipeline within pain management. We are truly excited about this partnership”

Tim Patrick, CEO Ventis Pharma
“The partnership between Cessatech and Ventis is a testament to the power of collaboration and mutual growth,” said Tim Patrick, CEO of Ventis Pharma. “Cessatech has developed a unique product that has the potential to provide a much-needed option for children experiencing pain during treatment for injury or procedures. We are excited to utilize our skills and experience to bring CT001 to patients. We anticipate that the combined opportunities would bring us a market opportunity in the range of $200-400M within 5 years”

Read the full release (link)